qrxpharma announces strategic partnership with, page-12

Let me be this first to point out that I mistakenly thought the recent deal was for MOXduo IV, not IR. My mistake. Obviously the potential market for oral opioids in the US is vastly larger than for an IV formulation.

The problem is that it is difficult to gauge the degree and speed of market adoption in a VERY competitive and crowded marketplace. However, 5% market penetration does not appear to me to be out of reach in the medium term.

Good luck to QRX holders. Your company has certainly achieved a very important milestone.